Dear Fellow Investor,

If you’re tired of the endless market swings and looking for a way to generate consistent income, then stop everything you’re doing and read this.

Your FREE copy of “The Money Press Method: How to Generate Consistent Income Using Weekly Options” is ready to ship (US customers only).

The Money Press Method is kinda like creating little AirBnB rental properties in the stock market that create weekly rent checks

Simply visit this page, and enter your details to claim your complimentary copy PLUS the complete Money Press Method tutorial bundle, FREE. (limited time)

Throughout the course of this comprehensive, 100-page book, you’ll learn everything from the basics of options to one of the most powerful strategies on the planet, the Money Press Method.

Here’s a glimpse of what you’ll get when you act today:

✔ INSTANT Digital Access to the Money Press Method before your book arrives

✔ Physical Copy of the guidebook rushed directly to your doorstep

✔ 2 Bonus Quick-Start Training Videos, including the Money Press Method strategy training, and the popular…

✔ “How To Get Started On $10,000 or Less” training

✔ Our highly-praised “Money Press On-Ramp” to get you profiting in as little as a few days

Normally this bundle retails for $79.00. But not today.

Right now, we’re giving away FREE hard copies of this guidebook -plus- the complete tutorial bundle right here.

Once you have the Money Press Method in hand, you’ll immediately discover these timely benefits:

• Weekly income potential (the Money Press gives you this while carefully managing risk)
• Because it’s a “market-neutral” strategy, the Money Press works under any set of market conditions, including NOW…
• Minimal Time Commitment: trades can be executed in approx. 30 minutes each week
• Sleep-At-Night protection is built right in – no more nervous checking your account day and night
• Small account OK! Trade the world’s top stocks (even if they’re $600, $700, or more) with accounts less than $10,000

And that’s just scratching the surface.

What People Are Saying About 
The Money Press Method

“I never thought I’d see the day, but last Thursday my account was up $150K in a single day! Compared to every other program I’ve tried, your methods rock! Keep those good trades coming!” – Jeff S., NC

“Thank you and your team for what you do. I’ve tried lots of investing and trading approaches and nothing compares with your methods.” – Sunil M., CA

“I have been sucked in by other programs and have not made a penny. You are the ONLY person I want to follow and have been for the last 2 years. Please keep up the GREAT work.” – J. Hurrell, FL

Remember, this offer is only available while supplies last. Claim your FREE book and tutorial bundle before it’s too late.

Claim Your FREE Book & Tutorial Bundle Bonuses Now!

Don’t miss out on this life-changing opportunity. Secure your copy and start your journey to consistent weekly income today.

To your success,

Preston James
Traders Edge Network

---

Just For You

2 ETFs to Play Both Sides of the Iran War Ceasefire

Author: Nathan Reiff. Date Posted: 5/4/2026. 

Key Points

• A multi-week ceasefire between the United States and Iran may have helped to calm the markets, but threats to oil and other industries remain.
• Investors might seek ETFs to make bets on multiple outcomes as negotiations continue.
• An oil-focused fund like USO would likely benefit if prices continue to ascend amid renewed attacks; JETS is an air travel ETF that may thrive if the war cools.
• Special Report: The Biggest IPO Ever: Claim Your Stake Today

As the U.S. war in Iran enters its third month, the market has seemingly stabilized after initial concerns about shocks to the energy industry and oil prices. However, ongoing political developments—including the ceasefire that began in early April—mean uncertainty remains a major factor. Investors may still see further volatility if the ceasefire ends and conflict resumes.

One way to play this unpredictability is through exchange-traded funds (ETFs), which allow portfolios to benefit from industry-specific surges. Below are two funds worth considering, depending on whether you have an optimistic or pessimistic view of future developments in the Middle East.

A Modestly Priced, Liquid Approach to Crude Oil

June 1st: The $1.75 Trillion “Ripple Effect” (Ad)

The projected SpaceX and xAI S-1 filing hits the SEC on June 1st – and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does.

But the real opportunity isn’t the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI’s Colossus infrastructure buildout – and a specific trigger in the S-1 could reprice it overnight.Get the ticker and full briefing before the June roadshow begins

The United States Oil Fund LP (NYSEARCA: USO) is one of the most popular exchange-traded products offering exposure to oil. As a commodity pool, USO holds oil futures in an attempt to track the daily price changes of light, sweet crude oil. Notably, this type of oil is predominant in the United States, meaning that USO may be uniquely tied to the domestic oil market.

For its specialized focus, USO charges an expense ratio of 0.60%. This is actually cheaper than many alternatives in the space, and as an added bonus, USO also offers excellent liquidity. Its one-month average trading volume hovers above 27 million, despite not being the largest fund by assets under management, which total about $1.9 billion.

As these figures suggest, USO is popular as a short-term trade among more active investors. This is partly because of the potential to capture gains from near-term movements in crude oil, but also because the fund’s futures contract approach means it is subject to contango. Investors looking for a long-term buy-and-hold fund to wait out developments in the Iran war may be better off elsewhere. Nonetheless, if the price of oil continues to rise—a result investors may find increasingly likely if a ceasefire does not hold and attacks resume—USO may be a good way to take advantage of that movement.

An Airline-Focused Fund Ready to Take Off If Fuel Supplies and Prices Normalize

Investors expecting the war to cool might look to one of the industries most negatively impacted by the conflict in the first place: airlines. Companies in this space have had to contend not only with supply and price pressures for jet fuel, but also with the potential for changes in routes and operations due to regional instability.

The U.S. Global Jets ETF (NYSEARCA: JETS) targets an index of air travel industry firms, including not only airlines themselves but also companies responsible for manufacturing and servicing planes, among other things. 

Though it’s a global fund, it is primarily focused on domestic names and holds many of the largest airline firms in the world. Delta Air Lines Inc. (NYSE: DAL), American Airlines Group Inc. (NASDAQ: AAL), and United Airlines Holdings Inc. (NASDAQ: UAL)collectively make up about a third of the fund’s portfolio.

The exclusive focus on air travel is unique to JETS, distinguishing it from a number of broader transportation funds, and this may make the fund particularly appealing to investors betting that diplomacy between the United States and Iran will improve. So far, JETS’ year-to-date performance reflects the opposite: the fund is down about 8% in 2026.

With an expense ratio exactly the same as USO’s, JETS provides a smaller asset base of about $725 million and lower trading volume, though that is not uncommon for an ETF with a niche strategy like this. Investors may also want to keep in mind that JETS does offer a dividend, though with a yield of 0.5%this is more of a passive income boost than a core dividend play.

To be sure, there are many other ETFs that would stand to benefit if the ceasefire continues or the war stops altogether. The more oil-dependent an industry is, the more investors might expect it to surge if that development takes place. Even broader developed- or emerging-markets funds may climb if the Strait of Hormuz is reopened and global shipping normalizes, allowing not only energy markets but global trade overall to stabilize once again.

---

More Reading from MarketBeat

Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

Authored by Jessica Mitacek. Article Posted: 5/8/2026. 

Key Points

• Following a settled legal dispute with Novo Nordisk, HIMS has transitioned from selling compounded weight-loss drugs to offering brand-name Wegovy and Ozempic.
• While the deal was finalized in March, investors are eager to see if this pivot will boost the top line or if the financial impact likely won’t be seen until Q2.
• Despite its recent rally, the stock remains highly volatile with short interest exceeding 35%. 
• Special Report: The Biggest IPO Ever: Claim Your Stake Today

Healthcare stocks have struggled in 2026. With a year-to-date (YTD) decline of about 6%, the sector has been the worst performer among all 11 S&P 500 sectors this year.

That weakness has shown up in the YTD losses of some of Big Pharma’s biggest names, but it has also weighed on mid-cap stocks like telehealth platform Hims & Hers Health (NYSE: HIMS), which is down more than 23% in 2026.

June 1st: The $1.75 Trillion “Ripple Effect” (Ad)

The projected SpaceX and xAI S-1 filing hits the SEC on June 1st – and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does.

But the real opportunity isn’t the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI’s Colossus infrastructure buildout – and a specific trigger in the S-1 could reprice it overnight.Get the ticker and full briefing before the June roadshow begins

One day after a major announcement from the U.S. Food & Drug Administration (FDA) sent HIMS shares up nearly 4%, the stock gave back those gains on Thursday, falling nearly 5% as traders locked in profits.

That wasn’t enough to derail the stock’s recent rally, however, which has seen HIMS gain nearly 32% over the past month and about 77% since its 52-week low on Feb. 27. As the company prepares to report Q1 2026 earnings on May 11, here’s what investors should watch.

Is the Novo Nordisk Partnership Already Paying Off?

Following a well-publicized legal dispute earlier this year with Denmark-based Novo Nordisk (NYSE: NVO)—the eighth-largest publicly traded pharmaceutical company in the world with a market cap of more than $204 billion—it’s been smooth sailing for Hims & Hers.

Since Novo Nordisk dropped its patent infringement lawsuit on March 9, HIMS has been on a tear. Not only did the Danish firm abandon its case, but it also reached a deal that allows Hims & Hers to sell Novo Nordisk’s brand-name Wegovy and Ozempic through its direct-to-consumer and virtual medical services platform.

As part of that deal, Hims & Hers agreed to stop advertising its compounded GLP-1 products. Given the FDA’s announcement that it is proposing semaglutide, tirzepatide, and liraglutide be excluded from its 503B bulks list, that decision could prove prescient for the company.

Wall Street will be watching to see how that deal has affected Hims & Hers’ top line. Although the strategic shift was announced on March 9, Novo Nordisk’s GLP-1 products were not available for sale through the online platform until March 26. Since the first quarter closed on March 31, those gross sales may not appear on Hims & Hers’ income statement until Q2.

Will Hims & Hers Continue to Show Subscriber Growth?

The market will also be watching for confirmation that Hims & Hers’ total subscriber count remains above 2.5 million, if not continues to grow from there. That benchmark was reached near the end of 2025 and marked an increase of more than 16% from the 2.2 million subscribers the company had at the end of 2024.

That growth appears to be sustainable, as Hims & Hers ended 2023 with 1.5 million subscribers. More important than the raw subscriber count, though, is the fact that the telehealth company generates 90% of its recurring revenue from its customer base.

Approximately 82% of users remain on the platform for more than three months. If Hims & Hers can show that retention remains strong, it should help support full-year guidance.

Meanwhile, analysts are expecting earnings per share (EPS) of around three to four cents, which would represent an estimated 90% year-over-year decline. That may already be priced in given the stock’s YTD performance, but a miss could accelerate selling.

The same goes for quarterly revenue, which consensus forecasts place in the range of $616 million to $619 million. Wall Street is already bracing for a “reset quarter” after revenue growth slowed from nearly 111% in Q1 2025 to less than 29% in Q4, so any surprise to the upside could spark another leg higher in the current rally.

Analysts Are Taking a Wait-and-See Approach

Despite an average 12-month price target of nearly $32, which implies potential upside of around 24%, Wall Street remains cautious on the stock.

Of the 17 analysts currently covering HIMS, four rate it a Buy, 12 rate it a Hold, and just one rates it a Sell. Overall, the stock carries a consensus Hold rating.

Institutional ownership of nearly 64% falls within the typical range for mid-cap companies. Outflows of $1.62 billion have nearly caught up with inflows of $1.8 billion over the past 12 months, after selling accelerated in Q4 2025. But that trend reversed in Q1, with institutional selling 88% lower than institutional buying.

With a high beta of 2.43, the inherently volatile stock is currently attracting significant bearish interest. Concerningly, more than 35% of the float—or nearly 70 million shares of the almost 228 million shares outstanding—is currently shorted.

Still, strong earnings could shift sentiment and bring the stock closer to the consensus analyst price target. Shareholders and prospective investors should mark their calendars for Monday, May 11, when Hims & Hers Health reports Q1 2026 results.

Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.

This email communication is a paid sponsorship for Traders Edge Network, a third-party advertiser of DividendStocks.com and MarketBeat. 

If you have questions about your account, please feel free to contact our U.S. based support team at contact@marketbeat.com.

If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 North Reid Place, Suite 620, Sioux Falls, SD 57103. U.S.A..

Read More: CODE RED: AI Meltdown Imminent?(From Paradigm Press)